Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,060.86 USD

1,060.86
452,590

+5.29 (0.50%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $1,065.30 +4.44 (0.42%) 9:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron

by Zacks Equity Research

Otter Tail, OraSure, BioMarin and Regeneron have been highlighted in this Screen of The Week article.

MAIA Soars 20% on Interim Results From Lung Cancer Study

by Zacks Equity Research

MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.

Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

by Zacks Equity Research

Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.

Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024

by Zacks Equity Research

Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.

Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.

Here's Why You Should Invest in Avadel (AVDL) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Counter Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), OraSure (OSUR) and BioMarin Pharmaceutical (BMRN) are well-poised to gain.

Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress

by Zacks Equity Research

Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US

by Zacks Equity Research

The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO

by Zacks Equity Research

Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.

Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day.

Ethan Feller headshot

Bull of the Day: Regeneron Pharmaceuticals (REGN)

by Ethan Feller

The Biotechnology company enjoys a litany of bullish catalysts on the horizon

Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU

by Zacks Equity Research

Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why

by Zacks Equity Research

After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.

Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use

by Zacks Equity Research

FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

by Zacks Equity Research

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know

by Zacks Equity Research

Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results

by Zacks Equity Research

Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.

Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now

by Zacks Equity Research

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

Acadia Healthcare (ACHC) Inks JV to Better Serve Texas Residents

by Zacks Equity Research

Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.

GSK to Buy Private Biotech, Strengthen Respiratory Pipeline

by Zacks Equity Research

GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.

Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint

by Zacks Equity Research

Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.

Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies

by Zacks Equity Research

Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.

Sweta Killa headshot

5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016

by Sweta Killa

The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.